An Authentic Update On Boston Scientific Corporation (BSX)

    Nanavaty Maulik, SVP & Pres, Neuromodulation, subtracted 3,039 shares of Boston Scientific Corporation (BSX) from its portfolio at the rate of $40.46 per share valuing $122,958 on Jun 17. The insider left behind 254,469 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Boston Scientific Corporation (BSX) was $42.98. Currently, the 1st Resistance Point for this stock is $43.38, with a 2nd Resistance Point sitting at $43.77. Meanwhile, this company’s stock has a 1st Support Level at $42.23 and a 2nd Support Level at $41.47. Boston Scientific Corporation (BSX) stock has gained $1.29, or 3.09%, in the past five days. In the last full month, these shares have gained $4.53, or 11.78%. In the past three months, this stock’s price has risen by $5.06, or 13.34%. This year-to-date, Boston Scientific Corporation (BSX) shares have gained $7.64, or 21.62%.

    Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Boston Scientific Corporation (BSX) stock, 80% of short-term indicators suggest that these shares are a “ Buy .” Meanwhile, 100% of medium-term indicators point to this stock being a “ Buy .” Looking further ahead, 33% of long-term indicators suggest that this stock is a “ Buy .”

    With 1,390,653 K shares outstanding, this company currently has a market capitalization of $59,770,264K. Boston Scientific Corporation (BSX) generates $9,823 M in annual sales, amounting to annual net income of $1,671 M. This stock has generated a 1-Year Total Return of 32.25%, a 3-Year Total Return of 83.60%, and a 5-year Total Return of 227.84%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.

    In the most recently-reported fiscal quarter, which ended in Mar-19, Boston Scientific Corporation (BSX) reported earnings of $0.35 per share. Wall Street analysts, on average, were expecting the company to report earnings of $0.36 per share, representing a -0.01 difference and 1.66% surprise. In the previous quarter ending in Dec-18, the reported earnings of $0.39 represented a 0.02 difference from the consensus estimate calling for $0.37 per share, which was a 4.87% surprise.

    For the current fiscal quarter, which is set to end in 06/2019, the average earnings estimate is $0.38 per share. This estimate came from a total of 10 Wall Street Analysts. Of those market experts, the high estimate was $0.39 and the low estimate was $0.37. In the year-ago quarter, Boston Scientific Corporation (BSX) generated per-share earnings of $0.41. If the analysts are correct about the current quarter’s earnings, the growth will be -7.32%.

    Turning our focus now to insider trading activity, there have been 15 purchases (55,465 shares in total) and 16 sale (126,597 shares in total) in the last 3 months. In the last 6 months, there have been 122 insider buys amounting to 1,315,592 shares and 138 insider sales amounting to 998,552 shares. In the past full year, 138 insider purchases were made (involving 1,493,516 shares) and 169 insider sell-offs equivalent to 1,599,226 shares.

    Moving onto liquidity, Boston Scientific Corporation (BSX) has a Current Ratio of 0.76, a Quick Ratio of 0.54 and a Cash Ratio of 0.15. Looking at this company’s capital structure, its Total Debt to Total Equity is 80.86, its Total Debt to Total Capital is 44.71, and its Total Debt to Total Assets is now 33.60. Looking even further ahead into the future, its Long-Term Debt to Equity is 55.04 and its Long-Term Debt to Total Capital is 30.43.